Active multiple myeloma suppresses and typically eliminates coexisting MGUS

John P Campbell, Jennifer L J Heaney, Sankalp Pandya, Zaheer Afzal, Martin F Kaiser, Roger G Owen, J Anthony Child, Walter M Gregory, Gareth J Morgan, Graham H Jackson, Chris M Bunce, Mark T Drayson

Research output: Contribution to journalArticle

1 Citation (Scopus)
79 Downloads (Pure)

Abstract

BACKGROUND: Myeloma is consistently preceded by premalignant monoclonal gammopathy of undetermined significance (MGUS). In >5% of MGUS patients there is a second MGUS clone (biclonal gammopathy of undetermined significance; BGUS), yet, at myeloma diagnosis, presentation of biclonal gammopathy myeloma (BGMy) is considered less frequent, implying that myeloma eradicates coexisting MGUS.

METHODS: In the largest study of its kind, we assessed BGMy frequency amongst 6399 newly diagnosed myeloma patients enrolled in recent UK clinical trials.

RESULTS: Compared to expected prevalence (i.e., >5% of MGUS have BGUS), only 58 of 6399 (0.91%) newly diagnosed myeloma patients had BGMy, indicating myeloma typically eliminates coexistent MGUS. In these 58 BGMy cases, the MGUS plasma cell clone was greatly suppressed in size compared to typical levels observed in conventional MGUS; contrarily, the MGUS clone did not inhibit the myeloma plasma cell clone in BGMy.

CONCLUSION: Myeloma eliminates the majority of competing MGUS, and when it does not, the MGUS clone is substantially reduced in size.British Journal of Cancer advance online publication, 20 July 2017; doi:10.1038/bjc.2017.229 www.bjcancer.com.

Original languageEnglish
Pages (from-to)835-839
JournalBritish Journal of Cancer
Early online date20 Jul 2017
DOIs
Publication statusPublished - 17 Sep 2017

Fingerprint

Monoclonal Gammopathy of Undetermined Significance
Multiple Myeloma
Clone Cells
Plasma Cells
Publications

Keywords

  • Journal Article

Cite this

Campbell, J. P., Heaney, J. L. J., Pandya, S., Afzal, Z., Kaiser, M. F., Owen, R. G., ... Drayson, M. T. (2017). Active multiple myeloma suppresses and typically eliminates coexisting MGUS. British Journal of Cancer, 835-839. https://doi.org/10.1038/bjc.2017.229

Active multiple myeloma suppresses and typically eliminates coexisting MGUS. / Campbell, John P; Heaney, Jennifer L J; Pandya, Sankalp; Afzal, Zaheer; Kaiser, Martin F; Owen, Roger G; Child, J Anthony; Gregory, Walter M; Morgan, Gareth J; Jackson, Graham H; Bunce, Chris M; Drayson, Mark T.

In: British Journal of Cancer, 17.09.2017, p. 835-839.

Research output: Contribution to journalArticle

Campbell, JP, Heaney, JLJ, Pandya, S, Afzal, Z, Kaiser, MF, Owen, RG, Child, JA, Gregory, WM, Morgan, GJ, Jackson, GH, Bunce, CM & Drayson, MT 2017, 'Active multiple myeloma suppresses and typically eliminates coexisting MGUS', British Journal of Cancer, pp. 835-839. https://doi.org/10.1038/bjc.2017.229
Campbell, John P ; Heaney, Jennifer L J ; Pandya, Sankalp ; Afzal, Zaheer ; Kaiser, Martin F ; Owen, Roger G ; Child, J Anthony ; Gregory, Walter M ; Morgan, Gareth J ; Jackson, Graham H ; Bunce, Chris M ; Drayson, Mark T. / Active multiple myeloma suppresses and typically eliminates coexisting MGUS. In: British Journal of Cancer. 2017 ; pp. 835-839.
@article{9013929d352542da8db33b96c1f0840b,
title = "Active multiple myeloma suppresses and typically eliminates coexisting MGUS",
abstract = "BACKGROUND: Myeloma is consistently preceded by premalignant monoclonal gammopathy of undetermined significance (MGUS). In >5{\%} of MGUS patients there is a second MGUS clone (biclonal gammopathy of undetermined significance; BGUS), yet, at myeloma diagnosis, presentation of biclonal gammopathy myeloma (BGMy) is considered less frequent, implying that myeloma eradicates coexisting MGUS.METHODS: In the largest study of its kind, we assessed BGMy frequency amongst 6399 newly diagnosed myeloma patients enrolled in recent UK clinical trials.RESULTS: Compared to expected prevalence (i.e., >5{\%} of MGUS have BGUS), only 58 of 6399 (0.91{\%}) newly diagnosed myeloma patients had BGMy, indicating myeloma typically eliminates coexistent MGUS. In these 58 BGMy cases, the MGUS plasma cell clone was greatly suppressed in size compared to typical levels observed in conventional MGUS; contrarily, the MGUS clone did not inhibit the myeloma plasma cell clone in BGMy.CONCLUSION: Myeloma eliminates the majority of competing MGUS, and when it does not, the MGUS clone is substantially reduced in size.British Journal of Cancer advance online publication, 20 July 2017; doi:10.1038/bjc.2017.229 www.bjcancer.com.",
keywords = "Journal Article",
author = "Campbell, {John P} and Heaney, {Jennifer L J} and Sankalp Pandya and Zaheer Afzal and Kaiser, {Martin F} and Owen, {Roger G} and Child, {J Anthony} and Gregory, {Walter M} and Morgan, {Gareth J} and Jackson, {Graham H} and Bunce, {Chris M} and Drayson, {Mark T}",
year = "2017",
month = "9",
day = "17",
doi = "10.1038/bjc.2017.229",
language = "English",
pages = "835--839",
journal = "British Journal of Cancer",
issn = "0007-0920",
publisher = "Nature Research",

}

TY - JOUR

T1 - Active multiple myeloma suppresses and typically eliminates coexisting MGUS

AU - Campbell, John P

AU - Heaney, Jennifer L J

AU - Pandya, Sankalp

AU - Afzal, Zaheer

AU - Kaiser, Martin F

AU - Owen, Roger G

AU - Child, J Anthony

AU - Gregory, Walter M

AU - Morgan, Gareth J

AU - Jackson, Graham H

AU - Bunce, Chris M

AU - Drayson, Mark T

PY - 2017/9/17

Y1 - 2017/9/17

N2 - BACKGROUND: Myeloma is consistently preceded by premalignant monoclonal gammopathy of undetermined significance (MGUS). In >5% of MGUS patients there is a second MGUS clone (biclonal gammopathy of undetermined significance; BGUS), yet, at myeloma diagnosis, presentation of biclonal gammopathy myeloma (BGMy) is considered less frequent, implying that myeloma eradicates coexisting MGUS.METHODS: In the largest study of its kind, we assessed BGMy frequency amongst 6399 newly diagnosed myeloma patients enrolled in recent UK clinical trials.RESULTS: Compared to expected prevalence (i.e., >5% of MGUS have BGUS), only 58 of 6399 (0.91%) newly diagnosed myeloma patients had BGMy, indicating myeloma typically eliminates coexistent MGUS. In these 58 BGMy cases, the MGUS plasma cell clone was greatly suppressed in size compared to typical levels observed in conventional MGUS; contrarily, the MGUS clone did not inhibit the myeloma plasma cell clone in BGMy.CONCLUSION: Myeloma eliminates the majority of competing MGUS, and when it does not, the MGUS clone is substantially reduced in size.British Journal of Cancer advance online publication, 20 July 2017; doi:10.1038/bjc.2017.229 www.bjcancer.com.

AB - BACKGROUND: Myeloma is consistently preceded by premalignant monoclonal gammopathy of undetermined significance (MGUS). In >5% of MGUS patients there is a second MGUS clone (biclonal gammopathy of undetermined significance; BGUS), yet, at myeloma diagnosis, presentation of biclonal gammopathy myeloma (BGMy) is considered less frequent, implying that myeloma eradicates coexisting MGUS.METHODS: In the largest study of its kind, we assessed BGMy frequency amongst 6399 newly diagnosed myeloma patients enrolled in recent UK clinical trials.RESULTS: Compared to expected prevalence (i.e., >5% of MGUS have BGUS), only 58 of 6399 (0.91%) newly diagnosed myeloma patients had BGMy, indicating myeloma typically eliminates coexistent MGUS. In these 58 BGMy cases, the MGUS plasma cell clone was greatly suppressed in size compared to typical levels observed in conventional MGUS; contrarily, the MGUS clone did not inhibit the myeloma plasma cell clone in BGMy.CONCLUSION: Myeloma eliminates the majority of competing MGUS, and when it does not, the MGUS clone is substantially reduced in size.British Journal of Cancer advance online publication, 20 July 2017; doi:10.1038/bjc.2017.229 www.bjcancer.com.

KW - Journal Article

U2 - 10.1038/bjc.2017.229

DO - 10.1038/bjc.2017.229

M3 - Article

SP - 835

EP - 839

JO - British Journal of Cancer

JF - British Journal of Cancer

SN - 0007-0920

ER -